Seres Therapeutics, Inc. 8-K

What Happened

• Seres Therapeutics, Inc. (MCRB) filed an 8-K (Item 5.02) on June 1, 2026, announcing that Hans‑Juergen Woerle, M.D., Ph.D., resigned from the company's board of directors and from the board committees on which he served, effective May 31, 2026. The filing states his departure was not due to any disagreement with the company regarding its operations, policies or practices.

Key Details

• Filing date: June 1, 2026 (Form 8-K, Item 5.02).
• Resignation effective: May 31, 2026.
• Director affected: Hans‑Juergen Woerle, M.D., Ph.D.
• Company statement: Departure not due to any disagreement with the company on operations, policies or practices.

Why It Matters

• This is a board-level change that affects Seres' governance. While the filing reports no disagreement or operational concerns, investors should note the reduced board membership and monitor future SEC filings or press releases for any appointment of a replacement or committee reassignments that could influence governance or strategic oversight.